Comparing ESA Dosing Regimens for Anemic Kidney Disease Patients
Pergola et al conducted a randomized, open label, multicenter study to test the hypothesis that extended dosing regimens of epoetin alfa would be as safe and effective as approved dosing regimens, concluding that extended dosing regimens were not inferior to the standard three times per week dosing regimen when used to treat anemia in subjects with stage 3-4 CKD. Unfortunately, the increased dose required for significant extension of the dosing interval would make this approach untenable in the anticipated environment of bundled payments for dialysis services. Until our understanding of the basic physiology improves, we will be continuing to use ESAs in a largely empirical fashion rather than based on the important and distinctive pharmacokinetics and pharmacodynamics of individual agents.
Read Full Summary and Expert Commentary »
Pergola PE, Gartenberg G, Fu M, Wolfson M, Rao S, Bowers P. A Randomized Controlled Study of Weekly and Biweekly Dosing of Epoetin Alfa in CKD Patients With Anemia. Clin J Am Soc Nephrol. 2009 Sep 17.